Castle Biosciences' i31-SLNB Test Outperforms MIA Nomogram in Melanoma Risk Assessment — Castle Biosciences, Inc.

Event summary

Castle Biosciences' DecisionDx-Melanoma's i31-SLNB test demonstrated superior accuracy in identifying low-risk patients for sentinel lymph node biopsy (SLNB) compared to the MIA nomogram.
The study found a 2.6% observed SLN positivity rate for low-risk patients classified by i31-SLNB, below the NCCN's 5% threshold, versus 5.8% for the MIA nomogram.
The prospective multicenter study evaluated 912 patients, reinforcing previous findings that integrating tumor biology improves risk assessment in melanoma care.

The big picture

This study underscores the growing shift toward molecular diagnostics in oncology, where tumor biology is increasingly integrated with clinical factors to personalize treatment decisions. Castle Biosciences' success highlights the strategic advantage of tests that reduce unnecessary procedures while improving patient outcomes—a trend likely to accelerate as precision medicine gains traction.

What we're watching

Adoption Dynamics: How quickly clinicians will integrate i31-SLNB into standard melanoma care protocols, given its demonstrated superiority over existing tools.
Regulatory Impact: Whether the NCCN guidelines will evolve to reflect the improved accuracy of molecular-based risk assessments like i31-SLNB.
Competitive Positioning: The pace at which Castle Biosciences can leverage this validation to expand its market share in melanoma diagnostics against nomogram-based approaches.